Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $379.7M
Founded date: 2016
Investors 9
Funding Rounds 3
| Date | Series | Amount | Investors |
| 18.12.2020 | Series C | $131.2M | - |
| 06.06.2020 | Series B | $98.5M | - |
| 03.10.2017 | Series A | $150M | - |
Mentions in press and media 17
| Date | Title | Description |
| 05.11.2024 | Sobi's New Leadership: A Strategic Shift in the Biopharmaceutical Landscape | In the ever-evolving world of biopharmaceuticals, leadership changes can signal new directions and strategies. Recently, Swedish Orphan Biovitrum AB (Sobi) announced the nomination of David Meek as the new Chair of the Board of Directors. T... |
| 05.11.2024 | Navigating Change in Biopharma: Leadership Shifts at Senhwa and Sobi | The biopharmaceutical landscape is a dynamic arena, where leadership changes can signal new directions and strategies. Recently, two companies, Senhwa Biosciences and Swedish Orphan Biovitrum AB (Sobi), have made significant appointments th... |
| 04.11.2024 | David Meek is proposed as new Chair of the Board of Directors of Sobi | David Meek is proposed as new Chair of the Board of Directors of Sobi Mon, Nov 04, 2024 21:00 CET Report this content The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of... |
| 18.12.2020 | Cullinan Oncology Completes $131.2 Million Series C Financing | - |
| 17.12.2020 | Cullinan Oncology Completes $131.2 Million Series C Financing | - |
| 17.12.2020 | Cullinan Oncology Closes $131.2 Million Series C Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announ... |
| 17.12.2020 | Cullinan Oncology, Inc. announced that it has received $131.200119 million in funding from a group of investors | Cullinan Oncology, LLC announced that it has issued 66,599,045 series C preferred stock at a price of $1.97 per share for gross proceeds of $131,200,119.65 on December 17, 2020. The series C round of funding was led by Foresite Capital Mana... |
| 11.06.2020 | Fueled with a fresh cash injection, Cullinan expands its pipeline with a bid to develop a new combination drug for the checkpoint class | Fresh off of a $98.5 million raise, Patrick Baeuerle’s team at Cullinan Oncology has a new subsidiary they’re bringing into the pack. This one, their 8th drug development operation, is called Cullinan MICA, named after a... |
| 06.06.2020 | Cullinan Oncology Completes $98.5 Million Series B Financing | - |
| 04.06.2020 | Cullinan Oncology Closes $98.5M Series B Financing Round | Cullinan Oncology, a Cambridge, Mass.-based oncology research company, closed a $98.5m Series B financing. New institutional investors and family offices participated in the financing alongside original commitments from founding investors M... |
Show more